Predicine to Present 15 Liquid Biopsy Studies at AACR 2024

HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) — Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15?ctDNA?studies?at AACR 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and disease mechanism studies.

Predicine to Present 15 Liquid Biopsy Studies at AACR 2024

LabNews Media LLC

labnews.ai 的主编是 Marita Vollborn 和 Vlad Georgescu。自 1994 年以来，他们一直是畅销书作家、科学作家和科学记者。更多关于他们的写作信息，请访问 X-Press Journalistenbüro (https://xpress-journalisten.com)。更多维基百科信息：关于 Marita：https://de.wikipedia.org/wiki/Marita_Vollborn 关于 Vlad：https://de.wikipedia.org/wiki/Vlad_Georgescu

查看完整简介